This application view consolidates identifiers, linked product and market authorization context, dossier structure, sequence history, and active authority obligations in one place. Regulatory teams use it to understand readiness and risk before publishing new sequences or responding to open questions. Cross-links to labeling and variations maintain lifecycle traceability for post-approval changes. Inspection readiness risk is calculated from overdue commitments, failed sequences, and unresolved high-risk correspondence for immediate action.

Application ID
APP-017
Application Number
SFDA-2023-0017
Procedure Type
sMAA
Status
Failed
Linked Product
Market Authorization
Singapore · SFDA
Dossier Structure View
DossierFormatVersionModulesModule BreakdownStatus
DOS-017NeeS1.9.25M1 (8), M2 (10), M3 (7), M4 (6), M5 (14)Approved
Sequence Timeline
2024-06-09
0017 · Response to Questions
Status: approved. ACK: 2023-12-21.
2023-11-15
0117 · Initial Marketing Authorisation
Status: completed. ACK: pending.
2022-05-22
0217 · Safety Update
Status: overdue. ACK: 2023-06-28.
2022-11-27
0317 · Urgent Safety Restriction
Status: pending. ACK: pending.
Open Questions and Commitments
QuestionDue DateRiskStatus
Question on comparative dissolution data2025-01-19highOverdue
Request for benefit-risk assessment addendum2025-04-28highIn Progress
Request for updated SmPC section 4.12025-02-12mediumOpen
CommitmentDue DatePriorityStatus
Provide carcinogenicity study report for 2-year rat study2025-08-22mediumIn Progress
Provide carcinogenicity study report for 2-year rat study2025-08-29mediumBlocked
Linked Labeling and Variations
Labeling ArtifactTypeVersionStatus
LBL-049PIL16.5In Progress
LBL-050SmPC16.8Active
VariationTypeStatusSubmitted
SFDA-2023-0017-V017Type IAActivepending
SFDA-2023-0017-V117MajorApproved2024-05-14
SFDA-2023-0017-V217MinorSubmitted2023-12-14
SFDA-2023-0017-V317Type IIDraft2023-01-01
SFDA-2023-0017-V417MinorOverdue2023-10-19
Inspection Readiness Risk Panel
Risk Score: 2 · Overdue commitments: 0, failed/blocked sequences: 0, high-risk questions: 2.
Recommended next step: resolve outstanding questions and commitments before next publishing cycle to reduce inspection exposure.